Effects of L-Dopa in Parkinson's Disease

Godwin-Austen, R B; Frears, C. C.; Tomlinson, E. B.; Kok, Howe Sen

doi:10.1016/s0140-6736(69)91417-2

Cited by 153 publications

(54 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is known that most patients with Parkinson's dis ease have a normal or low blood pressure [1], In the 1960s, when levodopa was introduced for the treatment of Parkinson's disease, and also in the early 1970s, hypo tension was reported among the side effects of levodopa therapy of less than 1 year duration [2][3][4], Early in the treatment with levodopa, hypotension was considered a transient phenomenon [5], Little attention was paid thereafter to the effect of levodopa on resting blood pres sure, although extensive studies were done of reflex changes in blood pressure in response to standing, tilting and isometric exercise, as an index of cardiovascular reflexes, and also of the effect of levodopa on these reflex changes in blood pressure [6][7][8][9][10][11]. In fact, it is still unknown whether any hypotensive effect remains in patients on long-term levodopa.…”

Section: Introductionmentioning

confidence: 99%

Hypotensive Effect of Long-Term Levodopa in Patients with Parkinson’s Disease

Iwasaki

Hamaguchi²,

Iwasaki³

et al. 1990

Eur Neurol

View full text Add to dashboard Cite

To study the hypotensive effect of L-dopa in patients with Parkinson’s disease on long-term L-dopa, the blood pressure (BP) was measured in 14 patients and 6 controls before 100 mg L-dopa plus decarboxylase inhibitor and for up to 180min after dosing. Plasma monoamines and motor functions were assessed. The mean BP was reduced between 60 and 180 min after dosing in the patients, whereas such a reduction was not observed in 5 patients from whom L-dopa was withheld and in controls who showed a high ratio of plasma dopamine compared to plasma L-dopa after dosing. The L-dopa-induced reduction in BP was thought to be due to a central nervous mechanism.

show abstract

Section: Introductionmentioning

confidence: 99%

Hypotensive Effect of Long-Term Levodopa in Patients with Parkinson’s Disease

Iwasaki

Hamaguchi²,

Iwasaki³

et al. 1990

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…2,3 Frequently used (disease-specific) disability scales, such as the ADL part of the Unified PD Rating Scale (UPDRS-ADL), 4 are sumscore-based. Consequently, all items have to be presented to all patients irrespective of their level of disability, which means that able patients as well as more disabled patients will be presented the same items, which may lead to ceiling and floor effects.…”

mentioning

confidence: 99%

The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease

Weisscher¹,

Post²,

Haan³

et al. 2007

Neurology

View full text Add to dashboard Cite

Objective: The aim of this study was to examine the clinimetric properties of the AMC Linear Disability Score (ALDS), a new generic disability measure based on Item Response Theory, in patients with newly diagnosed Parkinson disease (PD). Methods:A sample of 132 patients with PD was evaluated using the Hoehn and Yahr (H&Y), the Unified PD Rating Scale motor examination, the Schwab and England scale (S&E), the Short Form-36, the PD Quality of Life Questionnaire, and the ALDS. Results:The internal consistency reliability of the ALDS was good (␣ ϭ 0.95) with 55 items extending the sufficient item-total correlation criterion (r Ͼ 0.20). The ALDS was correlated with other disability measures (r ϭ 0.50 to 0.63) and decreasingly associated with measures reflecting impairments (r ϭ 0.36 to 0.37) and mental health (r ϭ 0.23 to Ϫ0.01). With regard to knowgroup validity, the ALDS indicated that patients with more severe PD (H&Y stage 3) were more disabled than patients with mild (H&Y stage 1) or moderate PD (H&Y stage 2) (p Ͻ 0.0001). The ALDS discriminated between more or less severe extrapyramidal symptoms (p ϭ 0.001) and patients with postural instability showed lower ALDS scores compared to patients without postural instability (p ϭ Ͻ 0.0001). Compared to the S&E (score 100% ϭ 19%), the ALDS showed less of a ceiling effect (5%). Conclusion:The AMC Linear Disability Score is a flexible, feasible, and clinimetrically promising instrument to assess the level of disability in patients with newly diagnosed Parkinson disease.

show abstract

“…Similarly, Chase and Watanabe [6] found equivalent (10 mm Hg) decreases in arterial pressure in the recumbent and upright positions during the administration of L-dopa. However, postural hypotension has been repeatedly observed [3,8,31]. This is presumably secondary to the presence in neuronal adrenergic storage terminals of dopamine which acts as a 'false transmitter'.…”

Section: Non-adrenergic Vasoconstrictorsmentioning

confidence: 99%

“…An instance of special interest is the orthostatic hypotension which accom panies administration of L-dopa for Parkinson's disease [3,8,18,31]. The availability of peripheral dopa-decarboxylase inhibitors [21] makes it possible to correct this and other side effects of L-dopa administration while retaining the central effect of therapeutic benefit in Parkinson's disease.…”

Section: Introductionmentioning

confidence: 99%

Effect of Selected Drugs on Arterial Pressure Response to Upright Posture

McNay

1976

Cardiology

View full text Add to dashboard Cite

Effects of L-Dopa in Parkinson's Disease

Cited by 153 publications

References 9 publications

Hypotensive Effect of Long-Term Levodopa in Patients with Parkinson’s Disease

Hypotensive Effect of Long-Term Levodopa in Patients with Parkinson’s Disease

The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease

Effect of Selected Drugs on Arterial Pressure Response to Upright Posture

Contact Info

Product

Resources

About